文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌调强放射治疗中非图像引导放疗与基于基准标记的图像引导放疗联合或不联合缩小边界的临床与剂量学比较

Clinical and Dosimetric Comparison Between Non-image Guided Radiation Therapy and Fiducial-Based Image Guided Radiation Therapy With or Without Reduced Margin in Intensity Modulated Radiation Therapy for Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2024-08-24

该研究比较了518例中高危前列腺癌患者接受调强放射治疗(IMRT)时,使用基准标记的图像引导放疗(IGRT)与非IGRT的结局和毒性。非IGRT组371例,IGRT组147例(其中IGRT-A组使用与非IGRT组相同的边界,IGRT-B组使用缩小边界)。结果显示,IGRT可降低急性和晚期毒性,缩小边界可进一步降低毒性,且不降低生化无复发生存率。

要点

  • IGRT组急性≥2级胃肠道毒性和晚期≥2级泌尿生殖毒性均低于非IGRT组。
  • IGRT-B组急性≥2级泌尿生殖毒性低于IGRT-A组。
  • 各组5年生化无复发生存率无显著差异。

核心结论

  • 在中高危前列腺癌的IMRT中,使用基准标记的IGRT相比非IGRT可降低急性和晚期毒性。
  • 在IGRT下缩小治疗计划边界可进一步降低毒性,且不降低生化无复发生存率。

研究设计与样本

  • 共518例中高危前列腺癌患者接受IMRT,剂量为78 Gy分39次,此前接受至少3个月的新辅助雄激素剥夺治疗。
  • 非IGRT组371例,IGRT组147例,IGRT组包括使用与非IGRT组相同边界的IGRT-A组和使用缩小边界的IGRT-B组。
  • 非IGRT组、IGRT-A组和IGRT-B组的中位随访时间分别为99个月、88个月和63个月。

主要发现

  • 非IGRT组、IGRT-A组和IGRT-B组的5年生化无复发生存率分别为88%、95%和98%(非IGRT vs IGRT-A,P = .396;IGRT-A vs IGRT-B,P = .426)。
  • 中危患者的5年生化无复发生存率分别为94%、93%和96%(非IGRT vs IGRT-A,P = .916;IGRT-A vs IGRT-B,P = .646)。
  • 高危患者的5年生化无复发生存率分别为87%、96%和100%(非IGRT vs IGRT-A,P = .500;IGRT-A vs IGRT-B,P = .483)。
  • 非IGRT组和IGRT-A组的急性≥2级胃肠道毒性发生率分别为17%和7%(P = .019),晚期≥2级泌尿生殖毒性发生率分别为28%和16%(P = .028)。
  • IGRT-A组和IGRT-B组的急性≥2级泌尿生殖毒性发生率分别为45%和21%(P = .003)。

关键数值与推荐

  • V60Gy指至少接受60Gy的体积,V70Gy指至少接受70Gy的体积。
  • IGRT-B组膀胱和直肠壁的所有V60Gy和V70Gy值均小于IGRT-A组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to compare the outcomes and toxicities between patients treated with image guided radiation therapy (IGRT) using fiducial markers and non-IGRT in intensity modulated radiation therapy (IMRT) for prostate cancer. METHODS AND MATERIALS: In total, 518 patients with intermediate- and high-risk prostate cancer received IMRT with 78 Gy in 39 fractions after neoadjuvant androgen deprivation therapy for at least 3 months. Of these patients, 371 were in the non-IGRT group and 147 in the IGRT group, including the IGRT-A group using the same margins as the non-IGRT group and the IGRT-B group using reduced margins. The median follow-up periods for the non-IGRT, IGRT-A, and IGRT-B groups were 99 months, 88 months, and 63 months, respectively. RESULTS: The 5-year biochemical recurrence-free survival rates in the non-IGRT, IGRT-A, and IGRT-B groups were 88%, 95%, and 98% (non-IGRT vs IGRT-A, P = .396; IGRT-A vs IGRT-B, P = .426), respectively. Those for intermediate- and high-risk patients were 94%, 93%, and 96% (non-IGRT vs IGRT-A, P = .916; IGRT-A vs IGRT-B, P = .646), respectively, and 87%, 96%, and 100% (non-IGRT vs IGRT-A, P = .500; IGRT-A vs IGRT-B, P = .483), respectively. For the non-IGRT and IGRT-A groups, the rates of acute grade ≥ 2 gastrointestinal toxicities and late grade ≥ 2 genitourinary toxicities were 17% and 7% (P = .019), respectively, and 28% and 16% (P = .028), respectively. In the IGRT-A and IGRT-B groups, the rates of acute grade ≥ 2 genitourinary toxicities were 45% and 21% (P = .003), respectively. All V60Gy = the volume at least received 60Gy and V70Gy = the volume at least received 70Gy values of the bladder and rectal walls in the IGRT-B group were smaller than those in the IGRT-A group. CONCLUSIONS: IGRT with fiducial markers results in lower acute and late toxicities compared with non-IGRT in IMRT for intermediate- and high-risk prostate cancer. Moreover, the toxicities are further decreased by reducing the margins in the treatment planning under IGRT. These processes do not decrease the biochemical recurrence-free survival rates.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Serizawa I, Kozuka T, Soyano T, et al. Clinical and Dosimetric Comparison Between Non-image Guided Radiation Therapy and Fiducial-Based Image Guided Radiation Therapy With or Without Reduced Margin in Intensity Modulated Radiation Therapy for Prostate Cancer. Adv Radiat Oncol. 2024. PMID: 39318861. doi:10.1016/j.adro.2024.101612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。